2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2463

Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Abstract Number: 2488

Golimumab Retention Rate in Patients with Rheumatoid Arthritis. Predictors of Long-Term Retention
Abstract Number: 1520

Golimumab Retention Rate in Patients with Spondyloarthitis. Differences between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2297

Golimumab Versus Tocilizumab in Uveitis Related to Refractory Juvenile Idiopathic Arthritis. National Multicenter Study of 33 Patients
Abstract Number: 1140

Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study
Abstract Number: 2069

Gout Is More Frequent in Sickle Cell Disease Than the General Population
Abstract Number: 1599

GRADE-Based Recommendations for the Diagnosis and Monitoring of Systemic Lupus Erythematosus in Canada
Abstract Number: 1237

Group Strength Training in Rheumatology Patients: Results of an Exercise Survey
Abstract Number: 1278

Growth and Puberty in Juvenile Dermatomyositis a Longitudinal Multinatinal Cohort Study
Abstract Number: 1832

Gut Dysbiosis Contributes to Autoimmune Pathogenesis in Lupus-Prone Mice
Abstract Number: 404

Gut Microbiota Modify Inflammatory Arthritis through Autoantibody Generation and Mucosal Cytokines Alteration
Abstract Number: 1574

Gut Microbiota Perturbations in Reactive Arthritis
Abstract Number: 1915

Gut-Derived TNF As Risk Factor for the Development of Sacroiliac Inflammation
Abstract Number: 1021

GWAS of Gout in Patients with Hyperuricemia Identified Many Possible New Candidate Risk Alleles
Abstract Number: 379

H Syndrome: Five New Cases from the United States with Novel Features and Responses to Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].